Loading...
Loading...
PRDS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 19.8M |
| Operating I/L | -21.5M |
| Other Income/Expense | 3.6M |
| Interest Income | 0.0M |
| Pretax | -17.8M |
| Income Tax Expense | -3.6M |
| Net Income/Loss | -14.2M |
Pardes Biosciences, Inc. is a clinical stage biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics for life-threatening diseases. Their lead candidate, PBI-0451, is in clinical development to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company generates revenue through the development and commercialization of these therapeutics, aiming to improve the lives of patients suffering from these conditions.
